Correlation of Bone Mineral Parameters with Anthropometric Measurements and the Effect of Glucocorticoids on Bone Mineral Parameters in Congenital Adrenal Hyperplasia
参考文献:1.Nimkarn S, Lin-Su K, New MI. Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia. Endocrinol Metab Clin N Am. 2009;38:699–718.CrossRef 2.Gussinyé M, Carrascosa A, Potau N, et al. Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia. Pediatrics. 1997;100:671–4.CrossRef PubMed 3.Paganini C, Radetti G, Livieri C, Braga V, Migliavacca D, Adami S. Height, bone mineral density and bone markers in congenital adrenal hyperplasia. Horm Res. 2000;54:164–8.CrossRef PubMed 4.Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18:1319–28.CrossRef PubMed 5.Chakhtoura Z, Bachelot A, Samara-Boustani D, et al. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency. Eur J Endocrinol. 2008;158:879–87.CrossRef PubMed 6.Baxter JD. Advances in glucocorticoid therapy. Adv Intern Med. 2000;45:317–49.PubMed 7.Petak S, Barbu CG, Yu EW, et al. The official positions of the international society for clinical densitometry: body composition analysis reporting. J Clin Densitom. 2013;16:508–19. 8.Khadilkar AV, Sanwalka NJ, Chiplonkar SA, Khadilkar VV, Mughal MZ. Normative data and percentile curves for dual energy X-ray absorptiometry in healthy Indian girls and boys aged 5–17 y. Bone. 2011;48:810–9.CrossRef PubMed 9.Elnecave RH, Kopacek C, Rigatto M, Keller Brenner J, de Castro JAS. Bone mineral density in girls with classical congenital adrenal hyperplasia due to CYP21 deficiency. J Pediatr Endocrinol Metab. 2008;21:1155–62.PubMed 10.Ekbote VH, Khadilkar AV, Chiplonkar SA, Khadilkar VV. Determinants of bone mineral content and bone area in Indian preschool children. J Bone Miner Metab. 2011;29:334–41.CrossRef PubMed 11.Hagenfeldt K, Martin Ritzén E, Ringertz H, Helleday J, Carlström K. Bone mass and body composition of adult women with congenital virilizing 21-hydroxylase deficiency after glucocorticoid treatment since infancy. Eur J Endocrinol. 2000;143:667–71.CrossRef PubMed 12.Sciannamblo M, Russo G, Cuccato D, Chiumello G, Mora S. Reduced bone mineral density and increased bone metabolism rate in young adult patients with 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2006;91:4453–8.CrossRef PubMed 13.Girgis R, Winter JS. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1997;82:3926–9.CrossRef PubMed 14.Cetinkaya S, Kara C. The effect of glucocorticoid replacement therapy on bone mineral density in children with congenital adrenal hyperplasia. J Pediatr Endocrinol Metab. 2011;24:265–9.PubMed 15.Reid IR, Evans MC, Wattie DJ, Ames R, Cundy TF. Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. Osteoporos Int. 1992;2:103–5.CrossRef PubMed 16.Bachelot A, Chakhtoura Z, Samara-Boustani D, Dulon J, Touraine P, Polak M. Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency. Int J Pediatr Endocrinol. 2010. doi:10.1155/2010/326275 .PubMedCentral PubMed
1. Department of Pediatrics, KanchiKamakoti CHILDS Trust Hospital & The CHILDS Trust Medical Research Foundation, 12-A, Nageswara Road, Nungambakkam, Chennai, 600034, Tamil Nadu, India 2. Department of Pediatric Endocrinology, Kanchi Kamakoti CHILDS Trust Hospital, Nungambakkam, Chennai, Tamil Nadu, India
刊物主题:Pediatrics; Gynecology;
出版者:Springer India
ISSN:0973-7693
文摘
Objective To correlate the bone mineral parameters [bone mineral content (BMC) and bone mineral density (BMD)] using Dual energy X ray Absorptiometry (DXA) scan with anthropometric measurements and to study the effect of glucocorticoid therapy on BMC/BMD in children with Congenital adrenal hyperplasia (CAH).